Equities

LianBio

LIANY:PKL

LianBio

Actions
  • Price (USD)0.32
  • Today's Change0.00 / 0.00%
  • Shares traded31.00
  • 1 Year change-79.22%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024 16:30 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Share price forecast

The one analyst offering a 12 month price target expects LianBio - ADR share price to rise to 4.80 in the next year from the last price of 0.32.
High1,400.0%4.80
Med1,400.0%4.80
Low1,400.0%4.80

Earnings history & estimates in USD

On Nov 13, 2023, LianBio - ADR reported 3rd quarter 2023 losses of -0.22 per share. This result exceeded the -0.33 consensus loss of the 3 analysts covering the company and under-performed last year's 3rd quarter results by 10.00%.
Average growth rate-3.83%
LianBio - ADR reported annual 2022 losses of -1.02 per share on Mar 27, 2023.
Average growth rate+82.14%
More ▼

Revenue history & estimates in USD

LianBio - ADR did not report revenues for the 3rd quarter 2023. However, during the 3rd quarter of the prior year the company reported revenues of 0.00.
Average growth rate0.00%
LianBio - ADR did not report revenues for the full year 2022. However, during the prior year the company reported revenues of 0.00.
Average growth rate0.00%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.